2008

Editorial
Stief CG
The above article is from European Urology Supplements July 2008

Muscle-Invasive Urothelial Carcinoma of the Bladder: Neoadjuvant Chemotherapy Enables Organ-Preserving Therapy in Carefully Selected Patients 
Heidenreich A 
Rebuttal from Author re: Axel Heidenreich. Muscle-Invasive Urothelial Carcinoma of the Bladder: Neoadjuvant Chemotherapy Enables Organ Preserving Therapy in Carefully Selected Patients. Eur Urol 2008;54:21–23 
Herr HW 

The above editorials are based on the following article:
Outcome of Patients Who Refuse Cystectomy after Receiving Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer 
Herr HW

Laparoscopic Radical Cystectomy-Where are We Really? 
Rassweiler J 
Based on:
Laparoscopic and Robotic Assisted Radical Cystectomy for Bladder Cancer: A Critical Analysis 
Haber G-P,  Crouzet S,  Gill IS

More Nomograms or Better Evidence of Efficacy: What Do We Need in Urologic Oncology? 
Catto JWF 
Rebuttal from Authors re: James W.F. Catto. More Nomograms or Better Evidence of Efficacy: What Do We Need in Urologic Oncology? Eur Urol 2008;54:11–12 
Shariat SF, Margulis V, Karakiewicz PI 

The above editorials are based on the following article:
Nomograms for Bladder Cancer 
Shariat SF, Margulis V, Lotan Y et al

Considerations on the Use of Urine Markers for Bladder Cancer 
van Rhijn BWG
Based on:
Urinary Markers in Bladder Cancer 
Vrooman OPJ, Witjes JA

What Matters - Early Start or Duration of Chemotherapy Instillation Regimens or Patient Characteristics? 
Kaasinen E
Based on:
Comparison of Three Schedules of Intravesical Epirubicin in Patients with Non–Muscle-Invasive Bladder Cancer 
Hendricksen K, Witjes WPJ, Idema JG, et al.
Reply from Author re: Eero Kaasinen. What Matters - Early Start or Duration of Chemotherapy Instillation Regimens or Patient Characteristics? Eur Urol 2008;53:882–5 
Witjes JA

Prostate-Sparing Cystectomy: Two Sides of the Moon
Muto G

Red Wine, Sex, and a Genius 
Bartoletti R,  Mondaini N, Cai T

Organ Preservation for T1G3 Bladder Cancer: Is It Feasible?
Thalmann G 
Based on:
Early Versus Deferred Cystectomy for Initial High-Risk pT1G3 Urothelial Carcinoma of the Bladder: Do Risk Factors Define Feasibility of Bladder-Sparing Approach? 
Denziger S, Fritsche H-M, Otto W et al

Bladder Cancer - Contemporary Dilemmas in Its Management 
Whelan  P
Based on:
Intravesical Pharmacotherapy for Non–Muscle-Invasive Bladder Cancer: A Critical Analysis of Currently Available Drugs, Treatment Schedules, and Long-Term Results 
Witjes JA and Hendricksen K.

2007

Cytoskeleton Fragments Unveiling Bladder Cancer 
van der Poel HG 
Based on:
Urinary CYFRA 21.1 Is Not a Useful Marker for the Detection of Recurrences in the Follow-Up of Superficial Bladder Cancer
Fernandez-Gomez J, Rodriguez-Martinez JJ , Barmadah SE et al

Intravesical Chemotherapy in Non–Muscle-Invasive Bladder Cancer: What Schedule and Duration of Treatment? 
Sylvester RJ 
Based on:
Long-term intravesical adjuvant chemotherapy further reduces the recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Gue´rin (BCG) in patients with non–muscle-invasive bladder carcinoma.
Friedrich MG, Uwe Pichlmeier  U,  Schwaibold H et al

What is the Optimal BCG Dose in Non–Muscle-Invasive Bladder Cancer? 
Witjes JA 
Based on:
A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C
Ojea A, Nogueira JL, Solsona E et al

It Is Time to Abandon the “Superficial” in Bladder Cancer 
Soloway MS